

NANO VIRICIDES, INC.  
Form 8-K  
December 15, 2017

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) **December 8, 2017**

**NANO VIRICIDES, INC.**  
(Exact Name of Registrant as Specified in Its Charter)

**Nevada** **000-1379006** **76-0674577**  
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

**1 Controls Drive,**  
**Shelton, Connecticut**  
(Address of Principal Executive Offices)

**06484**  
(Zip Code)

**(203) 937-6137**  
(Registrant's Telephone Number, Including Area Code)

Edgar Filing: NANOIRICIDES, INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

(a) On December 8, 2017, NanoViricides, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “Meeting”). Of the 63,307,000 shares of common stock entitled to vote at the Meeting, 50,820,517 shares of common stock were present in person or by proxy and 3,776,027 shares of Series A Convertible Preferred Stock (“Series A Preferred Shares”) were present in person or by proxy, representing approximately 82% of the Company’s outstanding voting capital stock.

(b) At the Meeting, the Company’s stockholders re-elected Dr. Anil Diwan, Dr. Milton Boniuk, and Dr. Mukund Kulkarni as Class I Directors, each for a two-year term expiring at the 2019 annual meeting of stockholders and until each of their respective successors are duly elected and qualified or until each of their respective earlier resignation or removal. The Company’s stockholders also ratified the appointment of Eisner Amper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2018. Each proposal is described in more detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on October 27, 2017.

The voting results of the shares of common stock for each proposal are set forth below:\*

**Proposal 1 – Election of All Directors:**

| Total Shares Voted | Votes Against | Total Votes Withheld | Percentage Voted For | Broker     |
|--------------------|---------------|----------------------|----------------------|------------|
|                    |               |                      |                      | Non-Votes  |
| 25,081,339         | 0             | 950,283              | 96.34%               | 24,788,895 |

Re-election of Dr. Anil Diwan as a Class I Director:

| Votes For   | Votes Against | Votes Withheld | Percentage Voted For |
|-------------|---------------|----------------|----------------------|
| 19,379,7920 | 6,651,839     |                | 74.45%               |

Re-election of Dr. Milton Boniuk as a Class I Director:

| <b>Votes For</b> | <b>Votes Against</b> | <b>Votes Withheld</b> | <b>Percentage<br/>Voted For</b> |
|------------------|----------------------|-----------------------|---------------------------------|
| 25,048,4190      | 983,203              |                       | 96.22%                          |

Re-election of Dr. Mukund Kulkarni as a Class I Director:

| <b>Votes For</b> | <b>Votes Against</b> | <b>Votes Withheld</b> | <b>Percentage<br/>Voted For</b> |
|------------------|----------------------|-----------------------|---------------------------------|
| 25,053,1320      | 978,490              |                       | 96.24%                          |

**Proposal 2-** To ratify the appointment of Eisner Amper, LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2018:

| <b>Votes For</b>    | <b>Votes Against</b> | <b>Votes Abstained</b> | <b>Percentage<br/>Voted For</b> | <b>Broker<br/>Non-Votes</b> |
|---------------------|----------------------|------------------------|---------------------------------|-----------------------------|
| 47,903,2502,534,794 | 382,473              |                        | 94.97%                          | 0                           |

\*These results do not include the votes of the 4,356,460 outstanding shares of the Company's outstanding Series A Convertible Preferred Stock, which votes the rate of 9 votes per share, and of which 3,776,027 shares voted in favor of each of Proposals 1 and 2.

**SIGNATURES**

**PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.**

**NANO VIRICIDES, INC.**

Date: December 14, 2017 By: */s/ Eugene Seymour, MD*

Name: Eugene Seymour

Title: Chief Executive Officer